1. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217–21.
2. Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS. Stroke risk as a function of atrial fibrillation duration and CHA2DS2-VASc score. Circulation. 2019 Nov 12;140(20):1639–46.
3. D’Souza A, Butcher KS, Buck BH. The multiple causes of stroke in atrial fibrillation: thinking broadly. Can J Cardiol. 2018 Nov;34(11):1503–11.
4. Lee SI, Sayers M, Lip GY, Lane DA. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. Int J Clin Pract. 2015 Nov;69(11):1341–8.
5. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. Am J Cardiol. 2017 Nov 15;120(10):1813–9.